DIA and the Food and Drug Administration (FDA) Office of Women’s Health (OWH), in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP) and Society for Women’s Health Research (SWHR), will host Partnerships to Advance Patient Recruitment and Retention in Clinical Research from October 14-15, in Rockville, MD.
This first FDA co-sponsored patient recruitment and retention conference will explore:
• Recruitment and retention barriers and motivations for different subgroup populations in clinical trials
• Regulatory and public health impact of the under-representation of women, elderly, and minority groups in clinical trials
• Current best practices to ensure adequate recruitment and retention of patients in clinical trials
• Innovative and successful solutions/strategies for recruiting and retaining diverse populations in clinical trials
Dr. Margaret A. Hamburg, MD, FDA Commissioner, will deliver a special video welcome address.
Additional expert speakers will include:
• Phyllis Greenberger, MSW, President and CEO, SWHR
• C. Noel Bairey Merz, MD, Cedars-Sinai Medical, Preventive and Rehabilitative Cardiac Center and, Women’s Health Program
• Sheila L. Thorne, Multicultural Healthcare, Marketing Group; Stony Brook University School of Social Welfare
• Kathleen B. Drennan, TrialAdvance, The Face of Clinical Trials
• Richard A. Williams, MD, FACC, UCLA School of Medicine; The Minority Health Institute, Inc.; The Association of Black Cardiologists, Inc.
• Joshua M. Sharfstein, MD (Keynote speaker), Principal Deputy Commissioner, FDA
• Vivian W. Pinn, MD (Keynote speaker), Office of the Director, National Institutes of Health (NIH), DHHS
“Recruiting adequate numbers of clinical trial participants representing demographic subgroups has improved, yet developing strategies for successfully recruiting and retaining these populations remains a challenge, says Kathleen B. Drennan, President and CEO, TrialAdvance, The Face of Clinical Trials. “This conference will allow key stakeholders including pharmaceutical companies, CROs, principal investigators, physicians, government, research institutions, and IRBs to engage in shared discussions and establish action plans eliminating disparities and advancing representation of subpopulations in clinical drug trials.”
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.